

DMD # 67694

Review

The complexities of interpreting reversible elevated serum creatinine levels in drug development: Does a correlation with inhibition of renal transporters exist?

Xiaoyan Chu, Kelly Bleasby, Grace Hoyee Chan, Irene Nunes, Raymond Evers

Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck Sharp & Dohme Corporation, Kenilworth, New Jersey, USA (XC, KB, GHC, RE); GRA Onc, Immunology, Biologics & Devices, Merck Sharp & Dohme Corporation, Kenilworth, New Jersey, USA (IN)

DMD # 67694

Running Title: Serum creatinine and inhibition of renal transporters

Corresponding Author:

Xiaoyan Chu, Ph.D.

Merck & Co, RY800-D211

126 East Lincoln Avenue

Rahway, NJ 07065, USA

Tel 732-594-0977; Fax 732-594-2382; e-mail xiaoyan_chu@merck.com

Number of text pages: 24

Number of tables: 3

Number of figures: 3

Number of references: 116

Number of words in abstract: 242

Number of words in introduction: 815

Non-standard abbreviations:

Serum creatinine (SCr), glomerular filtration rate (GFR), creatinine renal clearance (CL_{cr}), organic cation transporter 2 (OCT2), multidrug and toxin extrusion protein 1 and -2K (MATE1 and MATE2K), organic anion transporter 2 (OAT2), drug-drug interaction (DDI), *in vitro-in*

DMD # 67694

in vivo correlation (IVIVC), maximum plasma concentration (C_{max}), unbound maximum plasma concentration ($C_{max,u}$), acute kidney injury (AKI).

DMD # 67694

Abstract

In humans, creatinine is formed by a multistep process in liver and muscle and eliminated via the kidney by a combination of glomerular filtration and active transport. Based on current evidence, creatinine can be taken up into renal proximal tubule cells by the basolaterally localized organic cation transporter 2 (OCT2) and the organic anion transporter 2 (OAT2), and effluxed into the urine by the apically localized multidrug and toxin extrusion protein 1 (MATE1) and MATE2K. Drug induced elevation of serum creatinine (SCr) and/or reduced creatinine renal clearance (CL_{cr}) is routinely used as a marker for acute kidney injury (AKI). Interpretation of elevated SCr can be complex, because such increases can be reversible and explained by inhibition of renal transporters involved in active secretion of creatinine or other secondary factors such as diet and disease state. Distinction between these possibilities is important from a drug development perspective as increases in SCr can result in the termination of otherwise efficacious drug candidates. In this review, we discuss the challenges associated with using creatinine as a marker for kidney damage. Furthermore, in order to evaluate whether reversible changes in SCr can be predicted prospectively based on *in vitro* transporter inhibition data, an in depth *in vitro-in vivo* correlation analysis was conducted for sixteen drugs with in house and literature *in vitro* transporter inhibition data for OCT2, MATE1 and MATE2K, as well as total and unbound maximum plasma concentration (C_{max} and $C_{max,u}$) data measured in the clinic.

DMD # 67694

Introduction

Serum creatinine (SCr), an endogenous cation produced mainly by muscle metabolism, is the most widely used marker to assess renal injury (Tschuppert et al., 2007). Traditional monitoring for nephrotoxicity relies upon SCr measurements (Waikar et al., 2012). Creatinine is primarily filtered through the kidney through the glomeruli, but depending on a number of factors ~10-40% is actively secreted by the proximal tubule cells through transporter-mediated active uptake and efflux (Levey et al., 1988; Breyer and Qi, 2010). Therefore, alterations in glomerular filtration rate (GFR) and/or proximal tubular secretion of creatinine can lead to increases in SCr and decreases in the estimated creatinine clearance. Elevation of SCr often results in reduction of drug dose (Arya et al., 2013; Arya et al., 2014) and may lead to discontinuation of the development of potentially promising drug candidates. Therefore, it is critical to distinguish clinically relevant increases in SCr due to renal toxicity from the non-pathologic increase in SCr attributed to the inhibition of renal transporters. Mild to moderate and reversible elevation of SCr and decrease in creatinine renal clearance (CL_{cr}) has been reported, which can be attributed to inhibition of creatinine transporters without affecting renal function per se (Arya et al., 2013; Arya et al., 2014). This is supported by the clinical observation that several drugs such as cobicistat (Lepist et al., 2014), pyrimethamine (Opravil et al., 1993), cimetidine (Dubb et al., 1978), and trimethoprim (Berglund et al., 1975) lead to increased levels of SCr without affecting kidney function. Such observations have also been reported for several recently approved drugs, including crizotinib (Brosnan et al., 2014; Camidge et al., 2014) and dolutegravir (Koteff et al., 2012). Understanding the mechanism of active secretion of SCr and how drugs may interfere with this process is therefore important from both a drug development and clinical practice perspective where SCr is used as a marker of kidney injury.

DMD # 67694

Acute kidney injury (AKI) is a common condition that complicates up to 7% of all-hospital admissions and 25% of intensive care unit admissions (Klevens et al., 2007; Vaidya et al., 2008; Minejima et al., 2011). While progress has been made in understanding the pathophysiology of AKI and in the clinical care of patients with AKI, mortality rates have remained unchanged at 50-70% over the past 50 years (Minejima et al., 2011). Despite routine monitoring of systemic drug levels and renal function using traditional blood and urinary markers of kidney injury (e.g. creatinine, blood urea nitrogen, tubular casts, urinary concentrating ability), 10-20% of patients receiving aminoglycoside therapy, for instance, will develop AKI (Rybak et al., 1999). The lack of sensitive and specific markers of AKI limits the ability for early detection and intervention in drug-induced nephrotoxicity.

In the kidney, the elimination of drugs and endogenous compounds, such as creatinine, is the net result of passive glomerular filtration and reabsorption, as well as transporter-mediated active tubular secretion and/or reabsorption. The major transporters in human proximal tubule cells that play a role in the uptake of drugs and endogenous compounds from blood into proximal tubule cells are the organic cation transporter 2 (OCT2), and the organic anion transporters 1 and 3 (OAT1 and 3; Figure 1). In the apical membrane, major efflux transporters involved in the excretion of drugs into the urine are the multidrug and toxin extrusion protein 1 (MATE1) and MATE2K, and the multidrug-resistance protein MDR1 P-glycoprotein (P-gp). Inhibition of these transporters may alter systemic and tissue exposure of drugs, metabolites, and endogenous compounds, which may subsequently lead to clinically significant drug-drug interactions (DDIs). This can be of concern from a drug efficacy or safety perspective (Giacomini et al., 2010; Hillgren et al., 2013). Other transporters, such as the breast cancer resistance protein (BCRP), are also expressed in the proximal tubule (Figure 1), but their clinical significance is less well

DMD # 67694

defined (Giacomini et al., 2010; Giacomini and Huang, 2013; Hillgren et al., 2013). In general, drug transporters are promiscuous in substrate recognition and in addition to the charge of drugs, other factors, such as polar surface area, molecular weight, and number of hydrogen bond donors and acceptors, contribute to substrate specificity (Chang et al., 2006). Excellent reviews on renal transporters have been published previously and the reader is referred to these for further details (Masereeuw and Russel, 2010; Morrissey et al., 2013).

In this review we provide: 1) An overview of the biosynthesis and disposition of creatinine in humans; 2) The current knowledge of transporters involved in the active renal secretion of creatinine; 3) A discussion on potential mechanisms that could result in increased levels of SCr; 4) A retrospective analysis to assess the correlation of elevation of SCr and inhibition of the renal transporters OCT2, MATE1 and MATE2K, and a discussion on the challenges associated with the identification of reliable biomarkers for AKI; and 5) A discussion on whether creatinine is a predictive and sensitive biomarker for DDIs attributed to inhibition of OCT2 and MATEs.

Markers of renal function

GFR is generally accepted as the best index of renal function in health and disease (Levey et al., 2015) and it can be accurately assessed by the measurement of the clearance of an exogenous substance such as inulin, ^{99m}Tc-DPTA, ¹²⁵I-i-othlamate, or ⁵¹Cr-EDTA (Korhonen, 2015). However, as these methods are expensive and inconvenient for use in the clinical setting, GFR is routinely estimated (eGFR) from the measurement of SCr, using a variety of equations such as those recommended by the Modification of Diet in Renal Disease (MDRD) study (National

DMD # 67694

Kidney, 2002), and the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) (Levey et al., 2009), which take into account the impact of age, gender, and race on SCr.

The accuracy of the GFR estimate relies heavily upon the laboratory measurement of SCr. The inter-laboratory differences in the measurement of SCr have been widely documented (Miller et al., 2005; Seronie-Vivien et al., 2005). Miller et al. compared 50 methods of creatinine measurements in 5624 laboratories with an isotope-dilution mass spectrometry (IDMS) reference method and reported large bias and discrepancies between the methods and laboratories (Miller et al., 2005). For example, measurements ranged from 0.87-1.21 mg/dL for the 0.90 mg/dL creatinine reference sample. To put this into context, using the MDRD equation, a 0.1 mg/dL change in creatinine for a 60-year-old woman causes a 10% change in calculated GFR. More recently, the introduction of calibration standards which can be traced to the “gold standard” isotope-dilution mass spectrometry (IDMS) method has helped resolve these concerns (Korhonen, 2015).

During the last decade, there has also been increasing interest in cystatin C as an additional endogenous marker of renal function. Cystatin C, produced at a constant rate by human nucleated cells, is freely filtered, not actively secreted, or dependent on muscle mass or diet (Nyman et al., 2015). Equations combining serum cystatin C and creatinine have been proposed to provide a more accurate estimate of GFR (Inker et al., 2012).

Biosynthesis and disposition of creatinine

DMD # 67694

Creatinine is a product of the degradation of creatine, which is an organic nitrogenous compound playing an important role in cellular energy metabolism. Creatine is derived from dietary sources and *de novo* synthesis. As illustrated in Figure 2, the biosynthesis of creatine in humans accounts for ~50% of the daily requirement and is a two-step process: first guanidinoacetate is formed from arginine and glycine precursors, under the control of L-arginine-glycine amidinotransferase (AGAT), followed by the guanidoacetate methyl transferase (GAMT) catalyzed transfer of a methyl group from *S*-adenosyl-methionine to produce creatine. AGAT and GAMT activities have been reported in many tissues. However, they are most highly expressed in kidney and liver, respectively (Edison et al., 2007; Beard and Braissant, 2010). Creatine synthesis is balanced with that of dietary intake through feedback inhibition of AGAT. On a creatine free diet, this pathway is fully active. However, when creatine is ingested through the diet, AGAT is partially repressed and guanidinoacetate synthesis, and thus subsequent creatine synthesis, is reduced (Heymsfield et al., 1983). Once synthesized, creatine is released into blood circulation where it is taken up into muscle and other tissues by the Na⁺-Cl⁻ dependent creatine transporter SLC6A8 (Verhoeven et al., 2005). The majority (98%) of the total body creatine pool is found in skeletal muscle, with small amounts also found in brain, kidney, and liver (Heymsfield et al., 1983). Approximately 1.7% of the total creatine pool (creatine and phosphocreatine) dehydrates to creatinine per day (Edison et al., 2007) and permeates through the cell plasma membrane into the blood circulation.

As a low-molecular-weight cation (MW=113), creatinine is eliminated solely by renal excretion through a combination of glomerular filtration and tubular secretion, with minimal binding to plasma proteins and metabolism. Glomerular filtration, the passive process of ultrafiltration of

DMD # 67694

plasma from blood as it crosses the glomerular capillaries, accounts for the large majority of the renal elimination of creatinine (Levey et al., 2015), whereas the secretory component is estimated to be 10-20% of total creatinine elimination in some reports (Breyer and Qi, 2010) and up to 40% in others, under normal conditions (Levey et al., 1988). Net tubular reabsorption of creatinine is uncommon, but may occur in infants and the elderly (Musso et al., 2009). During chronic renal failure, the proportion of creatinine excreted by glomerular filtration decreases and the fraction undergoing tubular secretion may increase to 50-60%. In addition, under conditions of greatly reduced GFR, up to 60% of the daily creatinine generated may be eliminated by extra renal routes, such as degradation by intestinal microflora (Shemesh et al., 1985; Levey et al., 1988).

Beyond renal injury or disease, several factors are known to impact the formation and elimination of creatinine, including exercise, diet, emotional stress, age, fever and trauma, as well as inhibition of the secretory component by drugs (as discussed below) (Heymsfield et al., 1983; Levey et al., 1988). For example, creatinine excretion declines in the elderly and this is likely the result of several factors, including reduced muscle mass, decreased dietary protein consumption and the net tubular reabsorption of creatinine (Heymsfield et al., 1983; Musso et al., 2009).

Mathematical concepts of renal clearance of creatinine

The renal clearance of creatinine is determined by its glomerular filtration, tubular secretion, and reabsorption:

$$CL_{cr} = CL_{filtration} + CL_{secretion} - CL_{reabsorption} \text{ Eq. 1}$$

DMD # 67694

Where $CL_{\text{filtration}}$, $CL_{\text{secretion}}$, $CL_{\text{reabsorption}}$ represents creatinine clearance by renal filtration, tubular secretion, and reabsorption, respectively.

CL_{cr} can be described by Eq.2 (Shitara et al., 2005).

$$CL_{\text{cr}} = (1 - FR) \cdot (f_u \cdot GFR + CL_{\text{secretion}}) \\ = (1 - FR) \cdot (f_u \cdot GFR + (Q_R \cdot f_u \cdot CL_{\text{ser,int}} / Q_R + f_u \cdot CL_{\text{ser,int}})) \quad \text{Eq.2}$$

Where FR, f_u , GFR, Q_R , $CL_{\text{ser,int}}$ represents the fraction reabsorbed, protein unbound fraction in the blood, glomerular filtration rate, renal blood flow rate, and intrinsic clearance of tubular secretion, respectively.

As described below, tubular secretion of creatinine involves transporter-mediated active uptake and efflux. Therefore, $CL_{\text{ser,int}}$ is saturable and may be inhibited by drugs that are inhibitors of these transporters. FR may be in part saturable (Shitara et al., 2005), but the mechanism(s) contributing to reabsorption of creatinine, particularly, the role of transporters, are not well understood.

Imamura et al (Imamura et al., 2011) established mechanistic models to describe the renal elimination of creatinine. The model analysis suggested that active tubular secretion contributed significantly to the renal elimination of creatinine (30-60%), whereas the significance of reabsorption depended on the models used.

Transporters involved in active renal secretion of creatinine

Several drugs are reported to impact creatinine secretion, thereby causing transient increase in SCr without altering GFR (Table 2 and see below). The current hypothesis is that these changes are explained by the reversible inhibition of transporters involved in tubular secretion of

DMD # 67694

creatinine (German et al., 2012). We summarize in the sections below the current knowledge of the role of transporters in the uptake of creatinine into the proximal tubular cells of the kidney and efflux into the urine.

Transporters involved in creatinine uptake in the kidney

Renal uptake of creatinine has been studied by members of the SLC22A family, such as the organic cation transporters OCT2 and OCT3, and organic anion transporters OAT1, OAT2, and OAT3. Comprehensive reviews on these organic cation and anion transporters can be found in several publications (Jonker and Schinkel, 2004; Koepsell et al., 2007; Burckhardt, 2012; Nigam et al., 2015).

Expression and function of OCT2, OCT3, OAT1, OAT2 and OAT3

OCT2 is a renal organic cation uptake transporter primarily localized in the basolateral membrane of the whole segment of the renal proximal tubule cells. It plays a major role in renal uptake of mostly cationic compounds, but also transports some anionic and zwitterionic compounds (Jonker and Schinkel, 2004). On the contrary, OCT3 is recognized as an extraneuronal monoamine transporter (Jonker and Schinkel, 2004). It is widely expressed in many tissues, such as liver, kidney, skeletal muscle, placenta and heart, as well as in glial cells and epithelial cells of the choroid plexus, and neurons. OCT3 transports a wide range of monoamine neurotransmitters, hormones and steroids (Wu et al., 1998). OCT3 mRNA was detected in human kidney cortex; however, its level was much lower compared to OCT2 (Motohashi et al., 2002). Therefore, at least based on mRNA analysis, the importance of OCT3 in transport of cationic compounds in kidney is much less compared to OCT2 (Motohashi et al., 2002). Nevertheless, recent studies in Oct3 (-/-) knockout mice demonstrate that deletion of

DMD # 67694

Oct3 has an impact on pharmacokinetic and pharmacological effects of its substrates, such as metformin (Chen et al., 2015).

OAT1, OAT2, and OAT3 are renal organic anion uptake transporters located in the basolateral membrane of proximal tubules (Motohashi et al., 2002). OAT1 and OAT3 have overlapping substrate specificities, and are responsible for the uptake of many anionic drugs, such as antibiotics, antivirals, diuretics, uricosurics, statins, ACE inhibitors and antineoplastic drugs (Burckhardt, 2012). In contrast to OAT1 and OAT3, the role of OAT2 is less well characterized. More studies have emerged in this decade focusing on OAT2 expression in human kidney as well as its role in renal tubular handling of drugs (Cheng et al., 2012; Lepist et al., 2014; Shen et al., 2015). OAT2 is expressed in the basolateral membrane of renal proximal tubule cells as well as in the sinusoidal membrane of hepatocytes (Kobayashi et al., 2005; Cheng et al., 2012). One group showed that OAT2 was localized in both basolateral and apical membranes of human and cynomolgus monkey renal proximal tubules, but only in the apical membrane of rat proximal tubules (Shen et al., 2015). These findings suggest species differences for OAT2/Oat2 localization and possibly a role in reabsorption of OAT2 in primates. Species differences in OAT2/Oat2 localization make rodents a poor translatable model to predict effects in primates for substrates of this transporter. OAT2 has many substrates in common with OAT1 and OAT3. However, several antiviral drugs eliminated exclusively in the urine were preferentially transported by OAT2 and not by OAT1 and OAT3 (Cheng et al., 2012). OAT1, OAT2, and OAT3 mRNA are present in human kidney cortex, with highest mRNA level observed for OAT3, and different mRNA levels for OAT1 and OAT2 in two separate reports (Motohashi et

DMD # 67694

al., 2002; Cheng et al., 2012). However, it is not known whether these differences in mRNA levels translate into different amount of transporter protein.

Transporters involved in creatinine uptake

Creatinine has been reported to be an *in vitro* substrate for OCT2 (Urakami et al., 2004; Imamura et al., 2011; Ciarimboli et al., 2012; Lepist et al., 2014), with a Michaelis constant (K_m) range from 2 mM to 56 mM, suggesting low affinity transport. Based on the physiological concentration of creatinine in plasma (30-85 μ M), OCT2-mediated transport of creatinine will not be saturable, which is especially important for patients with reduced GFR (Urakami et al., 2004). *In vivo* studies using Oct1/2 double knockout mice showed the significance of Oct in creatinine secretion; creatinine clearance and renal accumulation of exogenous creatinine were 35-fold and 23-fold lower in Oct1/2 knockout mice compared to wild type mice, respectively (Ciarimboli et al., 2012). One group, however, questioned the role of Oct2 in creatinine transport as they did not observe significant difference in creatinine secretion in Oct1/2 knockout mice compared to control mice (Eisner et al., 2010). This discrepancy may be explained by the use of ketamine by Eisner et al. which has the potential to interfere with creatinine secretion (Ciarimboli et al., 2012). It should be noted that species differences may complicate the translation of the contribution of OCT2/Oct2 in creatinine transport from rodents to humans. For instance, in mouse, both Oct1 and Oct2 are expressed in kidney, while in humans, only OCT2 is expressed in kidney whereas OCT1 is predominantly expressed in liver (Jonker and Schinkel, 2004). More direct evidence of creatinine as an OCT2 substrate came from genome-wide association studies (GWAS) showing acute elevation of SCr (24% increase) in cancer patients following treatment with cisplatin, a known substrate and inhibitor of OCT2. The effect of

DMD # 67694

cisplatin on creatinine secretion is attributed primarily to competitive inhibition of OCT2 transport (Ciarimboli et al., 2012).

In a genetic association study, an intergenic single nucleotide polymorphism (SNP) (rs2504954; T->G), located on chromosome 6 in the region between the OCT2 and OCT3 genes, was significantly associated with higher SCr level (Ciarimboli et al., 2012). Another non-coding SNP (rs2279463; T>C) in the OCT2 gene was associated with creatinine metabolism (Kottgen et al., 2010). On the other hand, a coding SNP in OCT2 (rs316019; S270A) has been associated with reduced cisplatin-induced nephrotoxicity (Filipski et al., 2009) and reduced renal elimination of metformin (Wang et al., 2008), but not with altered SCr levels. An intronic OCT2 SNP (rs316009; G->A), a highly correlated polymorphism to rs316019, showed a strong association with tubular creatinine secretion and end-stage renal disease (Reznichenko et al., 2013). Taken together, both *in vitro* and *in vivo* data indicate a role of OCT2 in tubular secretion of creatinine.

Creatinine has also been reported to be an *in vitro* substrate for OCT3 (Imamura et al., 2011; Ciarimboli et al., 2012; Lepist et al., 2014). Similar to OCT2, OCT3 transports creatinine with a K_m in the mmolar range (~1.9 mM for OCT2 and ~1.3 mM for OCT3) (Lepist et al., 2014). Clinically significant polymorphisms have been identified in OCT3. It is unknown, however, whether these SNPs have an impact on creatinine secretion or not (Aoyama et al., 2006; Sakata et al., 2010). Based on current evidence, OCT3 is likely less important than OCT2 for creatinine uptake in kidney.

DMD # 67694

Opposing the traditional view of organic cationic pathways as the sole mechanism of creatinine secretion in kidney, creatinine has been reported to be an *in vitro* substrate for OAT2 (Ciarimboli et al., 2012; Lepist et al., 2014; Shen et al., 2015). A comprehensive analysis to identify the transporters for creatinine was performed, in which each transporter's mRNA and function were measured (Lepist et al., 2014). Creatinine showed somewhat higher affinity towards OAT2 ($K_m = 986 \mu\text{M}$), as compared to OCT2 and OCT3. Other groups also observed higher affinity transport of creatinine by OAT2 compared to that by other transporters (Shen et al., 2015). OAT2 might contribute to creatinine secretion, and possibly reabsorption in human renal proximal tubules, but clinical data are needed to support this hypothesis.

The role of OAT3 in creatinine secretion is unclear. Contradictory findings were observed *in vitro* in OAT3 transfected cell lines (Urakami et al., 2004), and kinetic data have not been reported. The involvement of mouse Oat3 in creatinine secretion is also unclear. Vallon et al. showed that creatinine was transported by mouse Oat3 using *Xenopus laevis* oocytes, and renal creatinine clearance was significantly reduced in Oat3 (-/-) compared to wild-type mice (Vallon et al., 2012). However, Ciarimboli et al. did not observe any creatinine uptake by mouse Oat3 in a transfected cell line (Ciarimboli et al., 2012). The contribution of OAT3 to renal creatinine uptake in human was estimated to be very low based on a relative activity factor evaluation (Imamura et al., 2011). For OAT1, several reports showed that creatinine was not a substrate for this transporter (Urakami et al., 2004; Imamura et al., 2011; Ciarimboli et al., 2012; Lepist et al., 2014).

Transporters involved in creatinine efflux in the kidney

DMD # 67694

Creatinine transport has been studied by members of the SLC47A family, such as MATE1 and MATE2K, and SLC22A family members, such as organic cation and carnitine transporters OCTN1 and OCTN2, and organic anion transporter OAT4.

Expression and function of MATE1, MATE2K, OCTN1, OCTN2 and OAT4

MATEs are proton/organic cation antiporters. MATE1 is highly expressed in the kidney, liver, adrenal gland, skeletal muscle and several other tissues, while MATE2K is specifically expressed in kidney (Masuda et al., 2006). Both MATE1 and MATE2K play a role in the renal tubular secretion of cationic drugs and endogenous compounds in humans (Yonezawa and Inui, 2011). OCTN1 and OCTN2 are organic cation transporters expressed in many tissues. They are localized at the brush border membrane of the proximal tubules in kidney and play a role in L-carnitine tissue distribution and renal reabsorption (Wu et al., 1999; Tamai, 2013). OAT4 is also located at the brush border membrane of proximal tubules and mediates the bidirectional transport of urate and some organic anions, in a substrate dependent manner (Miyazaki et al., 2005; Hagos et al., 2007).

Transporters involved in creatinine efflux

Creatinine has been reported to be a substrate for MATE1 and MATE2K (Tanihara et al., 2007). While MATEs function as efflux transporters *in vivo*, MATEs are often evaluated as uptake transporters by manipulating extracellular pH *in vitro*. In interpreting *in vitro* data for MATEs, it is assumed that the intra and extracellular binding sites have an equal affinity for substrates and inhibitors. *In vitro* studies suggest that MATE1 and MATE2K are involved in tubular secretion of creatinine (Tanihara et al., 2007; Lepist et al., 2014; Shen et al., 2015). The uptake window of

DMD # 67694

creatinine by MATEs at extracellular pH 8.4 was relatively low, and only ~ 2-3 fold higher in MATE1 and 1.3-3 fold higher in MATE2K transfected cells compared to control cells (Tanihara et al., 2007; Lepist et al., 2014; Shen et al., 2015). Intracellular acidification by pretreatment with ammonium chloride enhanced the uptake of creatinine by MATE1 and MATE2K (Tanihara et al., 2007). Kinetic analyses showed that creatinine has low affinity towards MATE1 and MATE2K, with K_m values of ~10 mM and ~21 mM, respectively (Shen et al., 2015). Orthologs of human MATE1, but not MATE2K, have been identified in rats and mice (Yonezawa and Inui, 2011). When studying the nephrotoxicity of cisplatin, a significant increase in creatinine was observed in cisplatin-treated *Mate1* knockout mice compared to control mice. In addition, the combination of pyrimethamine, a selective inhibitor of mouse *Mate1*, with cisplatin significantly increased creatinine levels compared to cisplatin alone in wild type mice. Both studies indirectly suggested a role of *Mate1* in creatinine transport, at least in mice (Nakamura et al., 2010).

Several polymorphisms have been identified in MATE1 (rs111060524-G64D, rs111060526-A310V, rs111060527-D328A, rs111060528-N474S), and MATE2K (rs111060529-K64N and rs111060532-G211V) in Japanese subjects, and these variants were associated with loss of transport activity of TEA and metformin *in vitro* (Kajiwara et al., 2009). Other MATE1 SNPs (rs35646404 -T159M and rs35790011-V338I) have also been described with similar reduction in transport activity of TEA and metformin in other subjects from various ethnic groups (Meyer zu Schwabedissen et al., 2010). The effect of these MATE1 and MATE2K variants on creatinine transport remains to be elucidated.

DMD # 67694

To date, no reports have demonstrated creatinine transport by OCTN1 and/or OCTN2. It is unclear whether creatinine is reabsorbed by proximal tubular cells through OAT4, as OAT4 functions as a bidirectional transporter (Hagos et al., 2007), suggesting that it could be involved in excreting substrates into urine and/or reuptake of substrates from urine into cells. Using different transfected cell lines, some observed creatinine uptake by OAT4 (Imamura et al., 2011), but this was not confirmed by others (Lepist et al., 2014).

In summary, based on current evidence, OCT2, MATE1 and MATE2K are the major transporters involved in renal creatinine secretion. OAT2 also could be involved based on *in vitro* evidence, but its *in vivo* relevance in humans is not clear yet.

Inhibition of renal transporters and elevation of SCr: an IVIVC analysis

In drug development, it is desirable to develop approaches to understand underlying mechanisms for interactions of drug candidates with active renal secretion of creatinine and to subsequently distinguish clinically relevant increases in SCr due to impairment of renal function from non-pathologic increases in SCr caused by inhibition of renal transporters. We therefore conducted a retrospective analysis to evaluate whether an *in vitro-in vivo* correlation (IVIVC) exists between inhibition of the renal transporters OCT2, MATE1, MATE2K, OAT2, and OCT3 and elevations of SCr and /or decreases in CL_{cr} . In this analysis (Tables 1 and 2), a total of 16 compounds were identified that showed: 1) $\geq 10\%$ reversible elevation of SCr without a significant change of measured GFR (cimetidine, pyrimethamine, trimethoprim, dronedarone, DX-619, dolutegravir, cobicistat, ritonavir, ranolazine, rilpivirine, and telaprevir); 2) $>10\%$ reversible elevation of SCr, without reported data on changes in GFR (amiodarone, vandetanib); and 3) No significant elevation of SCr and GFR and/or other renal toxicity markers at clinically relevant exposure as

DMD # 67694

negative *in vivo* controls (famotidine, ranitidine, and raltegravir). *In vitro* inhibition data (IC_{50} or K_i values) for human OCT2, MATE1, MATE2K, OAT2, and OCT3 were collected for these compounds from the University of Washington DDI database (<https://www.druginteractioninfo.org>). The range of IC_{50} or K_i values is summarized in Table 1. To better understand the correlation between *in vitro* inhibition of OCT2 and MATEs, and the elevation of SCr, *in vitro* IC_{50} values for inhibition of OCT2, MATE1 and MATE2K for 15 compounds listed in Table 1 were measured at Merck Research Laboratories using metformin as the probe substrate and the method described by Rizk et al. in CHO-K1-OCT2, CHO-K1-MATE1, and MDCKII-MATE2K cells (Rizk et al., 2013). Although creatinine is an ideal *in vitro* probe for IVIVC evaluations, its assay window in OCT2 and MATEs uptake assays is relatively low (our unpublished observations) (Lepist et al., 2014; Shen et al., 2015), and therefore it is unsuitable for measuring IC_{50} values.

IVIVC analysis in this review will be focused on OCT2 and MATEs. *In vitro* inhibition data for OAT2 and OCT3, which were recently identified as renal creatinine transporters, are currently available only for a few compounds (Table 1). These compounds generally show weak inhibition of OAT2 and OCT3 compared to MATEs and/or OCT2, suggesting that inhibition of these transporters might be clinically less relevant. Indomethacin is a relatively potent *in vitro* inhibitor of OAT2 ($IC_{50} = 2.1 \mu\text{M}$) (Shen et al., 2015). However, the effect of indomethacin on elevation of SCr in several clinical studies is controversial (Prescott et al., 1990; Al-Waili, 2002). In female healthy volunteers, indomethacin (150 mg daily for 3 days) had no significant effect on SCr, GFR, or renal blood flow (Prescott et al., 1990). However, indomethacin was reported to increase SCr in neonates (Al-Waili, 2002). As indomethacin is a potent prostaglandin synthesis

DMD # 67694

inhibitor, it is likely that mechanisms other than transporter inhibition could result in the observed elevation of blood creatinine (Al-Waili, 2002).

In vitro inhibition data with OCT2, MATE1 and MATE2K in the literature showed high variability for several compounds (Table 1). For instance, the *in vitro* IC₅₀ or K_i for ritonavir with MATE1 showed a 193-fold variability, and inhibition of OCT2 by trimethoprim and cimetidine showed a 101- and 99-fold variability, respectively. The reasons for this high variability are not understood, but could be caused by the use of different probe substrates, and differences in *in vitro* systems and assay conditions. For example, remarkable substrate-dependent difference in IC₅₀ values for inhibition of MATE2K by trimethoprim were reported (47-fold, metformin vs. N-methylnicotinamide as probes) (Muller et al., 2015), and for OCT2 inhibition by vandetanib (13-fold, MPP⁺ vs. metformin as probes) (Shen et al., 2013) when the studies were conducted in the same laboratory using the same *in vitro* system. Substrate-dependent inhibition of OCT2, MATE1, and MATE2K has been systematically systematically evaluated with several prototypic substrates (Belzer et al., 2013; Martinez-Guerrero and Wright, 2013), suggesting that both OCT2 and MATEs have multiple drug binding sites. In contrast to such substrate dependent inhibition, several other studies have shown consistent K_i or IC₅₀ values with selected OCT2/MATEs inhibitors across different probe substrates. For instance, Ito et al. reported no markedly substrate dependence in cimetidine K_i values for OCT2, MATE1, and MATE2K with five probe substrates (Ito et al., 2012b). Likewise, similar IC₅₀ values were obtained with cobicistat for OCT2 and MATE1 using TEA and creatinine as probe substrates (Lepist et al., 2014). Nevertheless, development of predictive DDI models for OCT2 and MATEs need to take into account the potential for substrate dependence of ligand interactions with these proteins. Furthermore, different *in vitro* systems and assay conditions may have a

DMD # 67694

marked effect on IC_{50} variability. For example, in studies where metformin was used as probe substrate, ritonavir IC_{50} for MATE1 was 0.08 μM when pre-incubating MATE1 transfected HEK 293 cells for 30 min in a 30 mM NH_4Cl buffer to create an artificial pH gradient (Wittwer et al., 2013), whereas the IC_{50} was 15.4 μM when using MATE1 transfected HeLa cells without pre-incubation with NH_4Cl (Meyer zu Schwabedissen et al., 2010).

In Table 2, the risk for *in vivo* inhibition of OCT2, MATE1 and MATE2K was assessed by comparing total and unbound maximal plasma concentrations (C_{max} and $C_{\text{max,u}}$) of test compounds with *in vitro* IC_{50} values (C_{max}/IC_{50} and $C_{\text{max,u}}/IC_{50}$). A cut-off of $C_{\text{max}}/IC_{50} \geq 0.1$ and $C_{\text{max,u}}/IC_{50} \geq 0.1$ was used to predict the risk for *in vivo* inhibition of respective transporters. As the relative contribution of these transporters (fraction transported) and the rate-determining step for renal secretion of creatinine are not well known, we assume that OCT2, MATE1, and MATE2K are contributing equally to the renal secretion of creatinine. Therefore, in assessing the existence of an IVIVC, inhibition of any of the above transporters was considered as an indication of *in vivo* inhibition of creatinine secretion as the worst case scenario. As shown in Table 2, using our in house IC_{50} data, $C_{\text{max}}/IC_{50} (\geq 0.1)$ provided a reasonably good prediction for the elevation of SCr for this set of compounds as there were no false negative predictions. Use of $C_{\text{max,u}}/IC_{50} (\geq 0.1)$ resulted in four false negatives (dronedarone, cobicistat, rilpivirine, and telaprevir). Both C_{max}/IC_{50} and $C_{\text{max,u}}/IC_{50}$ resulted in a false positive prediction for famotidine (40mg QD for 7days) and ranitidine.

Considering the variability of IC_{50} and K_i values reported in the literature, using lowest IC_{50} or K_i values for OCT2, MATE1, and MATE2K available for 11 compounds (Table 1), $C_{\text{max}}/IC_{50} (\geq 0.1)$ provided a reasonably good prediction for the elevation of SCr, whereas $C_{\text{max,u}}/IC_{50} (\geq 0.1)$ resulted in a false negative prediction for cobicistat (data not shown). Likewise, using the

DMD # 67694

highest IC_{50} or K_i values reported for OCT2, MATE1, and MATE2K, $C_{max}/IC_{50} (\geq 0.1)$ still provided a good prediction of the elevation of SCr, whereas $C_{max,u}/IC_{50} (\geq 0.1)$ resulted in false negative prediction for cobicistat, dolutegravir, ritonavir, and vandetanib. Use of either the lowest or highest IC_{50} literature values, C_{max}/IC_{50} and $C_{max,u}/IC_{50}$ both resulted in false positive predictions for famotidine (40mg QD for 7days) and ranitidine (data not shown). However, Hibma et al. (Hibma et al., 2015) have recently reported an elevation of SCr and a reduction in CL_{cr} by famotidine in humans at a single dose of 200 mg and multiple doses of 160 mg, which were 4-5 fold higher than in a previous report (Ishigami et al., 1989) (Table 2). The reason for the lack of IVIVC for these two compounds at clinically relevant exposure is unclear. As there are no major circulating metabolites for ranitidine and famotidine, it is less likely for metabolites to cause transporter inhibition. An effect on reabsorption of creatinine cannot be excluded, however.

Currently, $C_{max,u}/IC_{50} \geq 0.1$ is being recommended by the FDA for OCT2 (CDER, 2012.) and the International Transporter Consortium (ITC) for OCT2 and MATEs (Hillgren et al., 2013) as the cut-off value to assess the risk for DDIs with OCT2/MATEs transporters. For prediction of transporter related DDIs, it is critical to use relevant inhibitor concentrations, which are unbound inhibitor concentrations at the site of interactions with the transporter of interest. As such, $C_{max,u}$ will be the relevant concentration for predicting DDI with OCT2, which is localized in the basolateral plasma membrane of renal proximal tubule cells, whereas it may not be adequate to predict DDIs for efflux transporters, such as MATEs, as these are localized in the apical plasma membrane. For example, if the inhibitor is actively taken up by the proximal tubule cells, $C_{max,u}$ may under-estimate the inhibitory effects for efflux transporters. Thus, unbound intracellular inhibitor concentrations in relevant tissues would be more relevant for prediction of efflux

DMD # 67694

transporter related DDIs. However, the methodologies to measure and/or predict such values are currently still limited (Chu et al., 2013).

Is creatinine a sensitive biomarker for renal cationic transporter-related DDIs?

Determining the impact of perpetrator drugs on plasma concentration or urinary excretion of suitable endogenous biomarkers is a valuable tool to assess the risk for drug interactions early in drug development (e.g. Phase I clinical trials). Recently, some endogenous probes for studying renal cationic transporter related DDIs have been identified. Ito et al. have found that the endogenous metabolite N-methylnicotinamide (NMN), a substrate for OCT2, MATE1 and MATE2K, could be used as an endogenous probe to study the DDIs related to OCT2/MATEs inhibition in humans (Ito et al., 2012a). Pyrimethamine, a potent inhibitor of MATE1 and MATE2K near completely diminished tubular secretion of NMN (renal clearance 403 vs. 119 ml/min), but had minimal effect on plasma exposure of NMN. Furthermore, Muller et al. (Muller et al., 2015) reported that trimethoprim, another OCT2/MATEs inhibitor, decreased NMN renal clearance by 19.9% without significant impact on NMN plasma AUC. The magnitude of trimethoprim-induced renal clearance reduction was positively correlated between NMN and metformin in 12 subjects, suggesting the potential use of NMN as endogenous probe for DDIs involving OCT2/MATEs. Using untargeted metabolomics analysis of urine specimens from healthy subjects and mice treated with or without pyrimethamine, Kato et al. (Kato et al., 2014) found that thiamine, a vitamin B1, which is essential for carbohydrate metabolism and neural function, is also a potential biomarker for inhibition of MATE1 and MATE2K.

To evaluate if creatinine can be used as a biomarker to assess OCT2/MATEs related DDIs, we searched the literature for examples where clinical DDIs can be mechanistically explained by

DMD # 67694

inhibition of OCT2 and/or MATEs, and the changes in SCr or CL_{cr} were measured in the same clinical studies. As shown in Table 3, observed DDIs with several OCT2/MATEs inhibitors (cimetidine, pyrimethamine, trimethoprim, and vandetanib) at the dose indicated correlated with a 10-30% elevation in SCr or a decrease in CL_{cr}. This was not the case for ranitidine, however, as it caused DDIs with procainamide and triamterene without affecting SCr levels. Interestingly, famotidine, a recently reported MATE1 selective inhibitor, significantly increased SCr (200mg QD and 160mg q4hr) without affecting the plasma exposure of metformin (Hibma et al., 2015). The latter likely is explained by the opposing effects of the famotidine-induced increase in both metformin absorption and renal clearance. Elevation of SCr by cimetidine was variable and less sensitive in some DDI studies at the clinically relevant dose of 300-400 mg. Considering the weak to moderate change of SCr associated with OCT/MATEs related DDIs and that a range of other factors may potentially impact SCr exposure, as we have discussed elsewhere in this review, SCr does not appear to be a biomarker with sufficient sensitivity to assess the risk, either qualitatively or quantitatively, of inhibition of OCT2 or MATEs in humans. Follow-up mechanistic studies such as transporter inhibition experiments are still useful, however, in cases where increases in SCr exposure are observed.

Is serum creatinine an appropriate marker for renal injury?

Traditional monitoring for nephrotoxicity relies upon the measurement of SCr. However, SCr retains poor specificity for AKI and is insensitive to the degree of AKI for three reasons. First, a large amount of nephron loss can occur without significant changes in SCr due to residual renal reserve. This fact is most clearly evident in kidney donors in whom no significant change in SCr

DMD # 67694

occurs despite a loss of 50% of functioning renal mass (Bosch et al., 1983). Second, the rate of rise in SCr following a renal insult is delayed due to the kinetics of creatinine production from muscle turnover and accumulation secondary to reduced glomerular filtration. At a normal GFR of 120 mL/min, the serum half-life of creatinine is approximately 4 hours; however, at a GFR of 30 mL/min the half-life extends to 16 hours and will therefore not reach steady state for nearly 3 days (Waikar and Bonventre, 2009). Third, as previously discussed, SCr is influenced by a number of other factors including inhibition of tubular secretion by drugs, weight, gender, age, muscle metabolism, hydration state, and protein intake (Blantz, 1998). Reduced muscle mass secondary to malnutrition or immobility is a frequently observed clinical problem that severely limits the utility of SCr as a marker of kidney function. Based on the limitations of SCr, there has been great interest in the identification of alternate markers of renal function. To date, a number of promising biomarker candidates have been identified, characterized, and validated using models of kidney injury in animals or described for various clinical settings in humans such as sepsis, cardiac bypass surgery, and contrast media exposure (Fuchs and Hewitt, 2011; Waring and Moonie, 2011; Vanmassenhove et al., 2013). Importantly, the utility of these new biomarkers in detecting drug-induced AKI clinically in either the patient-care or drug development setting has not been established. Presently, urine biomarkers have been agreed by regulatory agencies to be used for nonclinical phases of drug development, and on a case-by-case basis for clinical drug development research investigation (Dieterle et al., 2010). Clinical qualification of novel AKI urine biomarkers for use during clinical drug development is currently on-going.

Conclusions

DMD # 67694

Based on the *in vitro* and pharmacogenomic evidence available, OCT2 is one of the transporters involved in the uptake of creatinine into kidney proximal tubule cells, but its quantitative involvement is unknown. More recent *in vitro* data suggests that OAT2 also transports creatinine efficiently, but to what extent this is relevant in humans is not yet clear. Following uptake into the kidney, MATE1 and MATE2K mediate the efflux of creatinine into the urine. Important questions that remain are whether uptake or efflux is rate-determining in the active secretion of creatinine, what the relative contribution is of each transporter in this process, and whether there are yet unidentified transporters involved in creatinine excretion and/or reabsorption. Similar to hepatobiliary transport, it is generally hypothesized that uptake is the rate-limiting step for active tubular secretion, if the luminal efflux is markedly greater than the basolateral efflux. In this case, the inhibition of the luminal efflux should have less impact on the overall systemic intrinsic clearance. However, this cannot explain the significant elevation of SCr by pyrimethamine, a selective inhibitor of MATEs relative to OCT2.

Currently, the effect of drugs on creatinine transport is measured in cell lines transfected with individual transporters. Recently, a quintuple *in vitro* transporter model expressing OAT2/OCT2/OCT3/MATE1/MATE2K has been explored to evaluate the impact of test compounds on creatinine transport (Zhang et al., 2015), but more data are needed to establish the predictive value of this model. Development and use of holistic models and integrated systems, for instance, immortalized cell lines derived from human kidney with preserved activity of transporters and drug metabolizing enzymes, may provide more physiologically relevant models to study the interaction of drugs with the renal secretion of creatinine in the future (Schophuizen et al., 2015).

DMD # 67694

Overall, high variability of *in vitro* transporter inhibition data, not limited to OCT2/MATEs, has become a significant concern and may limit IVIVE using universal cut-off values for transporter perpetrator decision trees which trigger clinical DDI studies (Bentz et al., 2013). Although the underlying mechanisms for IC₅₀ variability can be complex, proper standardization of *in vitro* inhibition assays by, for example, the use of clinically relevant probe substrates, and standardized incubation conditions, and cell lines will be helpful for improving IVIVE.

In an attempt to establish an IVIVC between inhibition of OCT2, MATE1 and MATE2K, several false negatives were identified using a cut-off for the ratio of C_{max,u}/IC₅₀ or C_{max,u}/K_i of ≥ 0.1 . The true positive rate was higher if total (bound plus unbound) drug concentrations were used for the analyses. Since only unbound drug will be available for interactions with transporters, this suggests that the free drug concentration measured in plasma is lower than in the proximal tubule cells or that mechanisms other than inhibition of MATEs and OCT2 contribute to the effects on creatinine. For example, although cobicistat is an inhibitor of MATE1 *in vitro*, this inhibition is not predicted to be clinically significant based on C_{max,u}/IC₅₀ data. Remarkably, famotidine and ranitidine were identified as inhibitors of MATEs and OCT2-mediated creatinine transport *in vitro*, whereas no effect on creatinine was observed at clinically relevant exposures. Currently, we have no good explanations for the lack of IVIVC for these compounds. In the future, use of mechanistic models may improve the prediction of *in vivo* interaction of drug molecules with creatinine renal transporters.

Due to potential interactions of drug molecules with creatinine secretion along with several other limitations, an alternative method to estimate GFR would be desirable. Despite ongoing efforts to identify more sensitive and specific markers for renal function and injury, currently, use of creatinine to estimate GFR is still a practical approach. As such, if a transient and /or reversible

DMD # 67694

elevation of SCr was observed during drug development, understanding the potential interaction of drug molecules with active renal secretion of creatinine and carefully monitoring renal function with alternate markers such as cystatin C would be recommended.

Since organic cation transporters such as OCT2 and MATEs are known to transport endogenous compounds (Jonker and Schinkel, 2004), it would be valuable from a drug development perspective if changes in these compounds could be used as biomarkers for assessing DDIs involving inhibition of these transporters. In the case of the kidney, excretion of such biomarkers would need to be excreted to a significant extent by active transport (as opposed to GFR), levels should not be affected by secondary factors such as diet and disease, not be sensitive to diurnal effects, and would need to be selective for the transporter(s) of interest. Based on these criteria and our retrospective analysis of *in vitro* and clinical data, creatinine is not an optimal biomarker as its synthesis involves multiple steps, external factors such as diet and exercise affect plasma levels, and the contribution of active transport to clearance is relatively small and not consistent between patient populations. However, mechanistic studies to explain increases in creatinine in the absence of a decrease in GFR will continue to be important.

DMD # 67694

Acknowledgement

The authors thank Dr. Lisa A. Shipley for continuous support; Robert Houle for technical assistance; and Drs Kathleen Cox, Nancy G. B. Agrawal, Sevgi Gurkan for valuable comments on the manuscript.

DMD # 67694

Authorship Contributions

Participated in research design: N/A

Contributed new reagents: N/A

Conducted experiments: Chan

Performed data analysis: Chu, Bleasby, Chan, Evers

Wrote or contributed to the writing of the manuscript: Chu, Bleasby, Chan, Nunes, Evers

DMD # 67694

References

- Al-Waili NS (2002) Increased urinary nitrite excretion in primary enuresis: effects of indomethacin treatment on urinary and serum osmolality and electrolytes, urinary volumes and nitrite excretion. *BJU Int* **90**:294-301.
- Aoyama N, Takahashi N, Kitaichi K, Ishihara R, Saito S, Maeno N, Ji X, Takagi K, Sekine Y, Iyo M, Harano M, Komiyama T, Yamada M, Sora I, Ujike H, Iwata N, Inada T and Ozaki N (2006) Association between gene polymorphisms of SLC22A3 and methamphetamine use disorder. *Alcohol Clin Exp Res* **30**:1644-1649.
- Arya V, Florian J, Marcus KA, Reynolds KS, Lewis LL and Sherwat AI (2013) Does an increase in serum creatinine always reflect renal injury? The case of Stribild(R). *J Clin Pharmacol*.
- Arya V, Yang X, Balimane P, Chinn L, Hinderling P, Vaidyanathan J, Zur AA, Wittwer MB and Zhang L (2014) Creatinine as an endogenous marker for renal function—emerging role of transporters in the overall assessment of renal toxicity *Clin Pharm Ther* **95**:S65.
- Beard E and Braissant O (2010) Synthesis and transport of creatine in the CNS: importance for cerebral functions. *J Neurochem* **115**:297-313.
- Belzer M, Morales M, Jagadish B, Mash EA and Wright SH (2013) Substrate-dependent ligand inhibition of the human organic cation transporter OCT2. *J Pharmacol Exp Ther* **346**:300-310.
- Bentz J, O'Connor MP, Bednarczyk D, Coleman J, Lee C, Palm J, Pak YA, Perloff ES, Reyner E, Balimane P, Brannstrom M, Chu X, Funk C, Guo A, Hanna I, Heredi-Szabo K, Hillgren K, Li L, Hollnack-Pusch E, Jamei M, Lin X, Mason AK, Neuhoff S, Patel A, Podila L, Plise E, Rajaraman G, Salphati L, Sands E, Taub ME, Taur JS, Weitz D, Wortelboer HM, Xia CQ, Xiao G, Yabut J, Yamagata T, Zhang L and Ellens H (2013) Variability in P-glycoprotein inhibitory potency (IC₅₀) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment decision criteria. *Drug Metab Dispos* **41**:1347-1366.
- Berglund F, Killander J and Pompeius R (1975) Effect of trimethoprim-sulfamethoxazole on the renal excretion of creatinine in man. *J Urol* **114**:802-808.
- Blackhall FH, O'Brien M, Schmid P, Nicolson M, Taylor P, Milenkova T, Kennedy SJ and Thatcher N (2010) A phase I study of Vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer. *J Thorac Oncol* **5**:1285-1288.
- Blantz RC (1998) Pathophysiology of pre-renal azotemia. *Kidney Int* **53**:512-523.
- Bosch JP, Saccaggi A, Lauer A, Ronco C, Belledonne M and Glabman S (1983) Renal functional reserve in humans. Effect of protein intake on glomerular filtration rate. *Am J Med* **75**:943-950.
- Breyer MD and Qi Z (2010) Better nephrology for mice—and man. *Kidney Int* **77**:487-489.
- Brosnan EM, Weickhardt AJ, Lu X, Maxon DA, Baron AE, Chonchol M and Camidge DR (2014) Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib. *Cancer* **120**:664-674.
- Burckhardt G (2012) Drug transport by Organic Anion Transporters (OATs). *Pharmacol Ther* **136**:106-130.
- Camidge DR, Brosnan EM, DeSilva C, Koo PJ and Chonchol M (2014) Crizotinib effects on creatinine and non-creatinine-based measures of glomerular filtration rate. *J Thorac Oncol* **9**:1634-1637.
- CDER USFaDAF (2012.) U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry, drug interaction studies—study design, data analysis, implications for dosing, and labeling recommendations. February 2012
<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf>.

DMD # 67694

- Chang C, Ekins S, Bahadduri P and Swaan PW (2006) Pharmacophore-based discovery of ligands for drug transporters. *Adv Drug Deliv Rev* **58**:1431-1450.
- Chen EC, Liang X, Yee SW, Geier EG, Stocker SL, Chen L and Giacomini KM (2015) Targeted disruption of organic cation transporter 3 attenuates the pharmacologic response to metformin. *Mol Pharmacol* **88**:75-83.
- Cheng Y, Vapurcuyan A, Shahidullah M, Aleksunes LM and Pelis RM (2012) Expression of organic anion transporter 2 in the human kidney and its potential role in the tubular secretion of guanine-containing antiviral drugs. *Drug Metab Dispos* **40**:617-624.
- Chu X, Korzekwa K, Elsby R, Fenner K, Galetin A, Lai Y, Matsson P, Moss A, Nagar S, Rosania GR, Bai JP, Polli JW, Sugiyama Y and Brouwer KL (2013) Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver. *Clin Pharmacol Ther* **94**:126-141.
- Ciarimboli G, Lancaster CS, Schlatter E, Franke RM, Sprowl JA, Pavenstadt H, Massmann V, Guckel D, Mathijssen RH, Yang W, Pui CH, Relling MV, Herrmann E and Sparreboom A (2012) Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients. *Clin Cancer Res* **18**:1101-1108.
- Cohen C, Elion R, Ruane P, Shamblaw D, DeJesus E, Rashbaum B, Chuck SL, Yale K, Liu HC, Warren DR, Ramanathan S and Kearney BP (2011) Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. *Aids* **25**:F7-12.
- Deray G, Bochet M, Katlama C and Bricaire F (1998) [Nephrotoxicity of ritonavir]. *Presse Med* **27**:1801-1803.
- Dieterle F, Sistare F, Goodsaid F, Papaluca M, Ozer JS, Webb CP, Baer W, Senagore A, Schipper MJ, Vonderscher J, Sultana S, Gerhold DL, Phillips JA, Maurer G, Carl K, Laurie D, Harpur E, Sonee M, Ennulat D, Holder D, Andrews-Cleavenger D, Gu YZ, Thompson KL, Goering PL, Vidal JM, Abadie E, Maciulaitis R, Jacobson-Kram D, Defelice AF, Hausner EA, Blank M, Thompson A, Harlow P, Throckmorton D, Xiao S, Xu N, Taylor W, Vamvakas S, Flamion B, Lima BS, Kasper P, Pasanen M, Prasad K, Troth S, Bounous D, Robinson-Gravatt D, Betton G, Davis MA, Akunda J, McDuffie JE, Suter L, Obert L, Guffroy M, Pinches M, Jayadev S, Blomme EA, Beushausen SA, Barlow VG, Collins N, Waring J, Honor D, Snook S, Lee J, Rossi P, Walker E and Mattes W (2010) Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium. *Nat Biotechnol* **28**:455-462.
- Dubb JW, Stote RM, Familiar RG, Lee K and Alexander F (1978) Effect of cimetidine on renal function in normal man. *Clin Pharmacol Ther* **24**:76-83.
- Dumitras S, Sechaud R, Drollmann A, Pal P, Vaidyanathan S, Camenisch G and Kaiser G (2013) Effect of cimetidine, a model drug for inhibition of the organic cation transport (OCT2/MATE1) in the kidney, on the pharmacokinetics of glycopyrronium. *Int J Clin Pharmacol Ther* **51**:771-779.
- Dutt MK, Moody P and Northfield TC (1981) Effect of cimetidine on renal function in man. *Br J Clin Pharmacol* **12**:47-50.
- Edison EE, Brosnan ME, Meyer C and Brosnan JT (2007) Creatine synthesis: production of guanidinoacetate by the rat and human kidney in vivo. *Am J Physiol Renal Physiol* **293**:F1799-1804.
- Eisner C, Faulhaber-Walter R, Wang Y, Leelahavanichkul A, Yuen PS, Mizel D, Star RA, Briggs JP, Levine M and Schnermann J (2010) Major contribution of tubular secretion to creatinine clearance in mice. *Kidney Int* **77**:519-526.
- Feng B, Obach RS, Burstein AH, Clark DJ, de Morais SM and Faessel HM (2008) Effect of human renal cationic transporter inhibition on the pharmacokinetics of varenicline, a new therapy for smoking cessation: an in vitro-in vivo study. *Clin Pharmacol Ther* **83**:567-576.

DMD # 67694

- Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH and Sparreboom A (2009) Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. *Clin Pharmacol Ther* **86**:396-402.
- Fuchs TC and Hewitt P (2011) Biomarkers for drug-induced renal damage and nephrotoxicity-an overview for applied toxicology. *AAPS J* **13**:615-631.
- German P, Liu HC, Szwarcberg J, Hepner M, Andrews J, Kearney BP and Mathias A (2012) Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. *J Acquir Immune Defic Syndr* **61**:32-40.
- Giacomini KM and Huang SM (2013) Transporters in drug development and clinical pharmacology. *Clin Pharmacol Ther* **94**:3-9.
- Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ and Zhang L (2010) Membrane transporters in drug development. *Nat Rev Drug Discov* **9**:215-236.
- Grun B, Kiessling MK, Burhenne J, Riedel KD, Weiss J, Rauch G, Haefeli WE and Czock D (2013) Trimethoprim-metformin interaction and its genetic modulation by OCT2 and MATE1 transporters. *Br J Clin Pharmacol* **76**:787-796.
- Hagos Y, Stein D, Ugele B, Burckhardt G and Bahn A (2007) Human renal organic anion transporter 4 operates as an asymmetric urate transporter. *J Am Soc Nephrol* **18**:430-439.
- Heymsfield SB, Arteaga C, McManus C, Smith J and Moffitt S (1983) Measurement of muscle mass in humans: validity of the 24-hour urinary creatinine method. *Am J Clin Nutr* **37**:478-494.
- Hibma JE, Zur AA, Castro RA, Wittwer MB, Keizer RJ, Yee SW, Goswami S, Stocker SL, Zhang X, Huang Y, Brett CM, Savic RM and Giacomini KM (2015) The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin. *Clin Pharmacokinet*.
- Hilbrands LB, Artz MA, Wetzels JF and Koene RA (1991) Cimetidine improves the reliability of creatinine as a marker of glomerular filtration. *Kidney Int* **40**:1171-1176.
- Hillgren KM, Keppler D, Zur AA, Giacomini KM, Stieger B, Cass CE and Zhang L (2013) Emerging transporters of clinical importance: an update from the International Transporter Consortium. *Clin Pharmacol Ther* **94**:52-63.
- Imamura Y, Murayama N, Okudaira N, Kurihara A, Okazaki O, Izumi T, Inoue K, Yuasa H, Kusuhara H and Sugiyama Y (2011) Prediction of fluoroquinolone-induced elevation in serum creatinine levels: a case of drug-endogenous substance interaction involving the inhibition of renal secretion. *Clin Pharmacol Ther* **89**:81-88.
- Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YL, Coresh J and Levey AS (2012) Estimating glomerular filtration rate from serum creatinine and cystatin C. *N Engl J Med* **367**:20-29.
- Ishigami M, Sezai Y, Shimada Y, Maeda T and Yabuki S (1989) Effects of famotidine, a new histamine H₂-receptor antagonist, on renal function. *Nihon Jinzo Gakkai Shi* **31**:687-691.
- Ito S, Kusuhara H, Kumagai Y, Moriyama Y, Inoue K, Kondo T, Nakayama H, Horita S, Tanabe K, Yuasa H and Sugiyama Y (2012a) N-methylnicotinamide is an endogenous probe for evaluation of drug-drug interactions involving multidrug and toxin extrusions (MATE1 and MATE2-K). *Clin Pharmacol Ther* **92**:635-641.
- Ito S, Kusuhara H, Yokochi M, Toyoshima J, Inoue K, Yuasa H and Sugiyama Y (2012b) Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. *J Pharmacol Exp Ther* **340**:393-403.
- Johansson S, Read J, Oliver S, Steinberg M, Li Y, Lisbon E, Mathews D, Leese PT and Martin P (2014) Pharmacokinetic evaluations of the co-administrations of vandetanib and metformin, digoxin, midazolam, omeprazole or ranitidine. *Clin Pharmacokinet* **53**:837-847.

DMD # 67694

- Jonker JW and Schinkel AH (2004) Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). *J Pharmacol Exp Ther* **308**:2-9.
- Kajiwara M, Terada T, Ogasawara K, Iwano J, Katsura T, Fukatsu A, Doi T and Inui K (2009) Identification of multidrug and toxin extrusion (MATE1 and MATE2-K) variants with complete loss of transport activity. *J Hum Genet* **54**:40-46.
- Kato K, Mori H, Kito T, Yokochi M, Ito S, Inoue K, Yonezawa A, Katsura T, Kumagai Y, Yuasa H, Moriyama Y, Inui K, Kusahara H and Sugiyama Y (2014) Investigation of endogenous compounds for assessing the drug interactions in the urinary excretion involving multidrug and toxin extrusion proteins. *Pharm Res* **31**:136-147.
- Klevens RM, Edwards JR, Richards CL, Jr., Horan TC, Gaynes RP, Pollock DA and Cardo DM (2007) Estimating health care-associated infections and deaths in U.S. hospitals, 2002. *Public Health Rep* **122**:160-166.
- Kobayashi Y, Ohshiro N, Sakai R, Ohbayashi M, Kohyama N and Yamamoto T (2005) Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). *J Pharm Pharmacol* **57**:573-578.
- Koepsell H, Lips K and Volk C (2007) Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. *Pharm Res* **24**:1227-1251.
- Korhonen PE (2015) How to assess kidney function in outpatient clinics. *Int J Clin Pract* **69**:156-161.
- Koteff J, Borland J, Chen S, Song I, Peppercorn A, Koshiha T, Cannon C, Muster H and Piscitelli SC (2012) A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects. *Br J Clin Pharmacol* **75**:990-996.
- Kottgen A, Pattaro C, Boger CA, Fuchsberger C, Olden M, Glazer NL, Parsa A, Gao X, Yang Q, Smith AV, O'Connell JR, Li M, Schmidt H, Tanaka T, Isaacs A, Ketkar S, Hwang SJ, Johnson AD, Dehghan A, Teumer A, Pare G, Atkinson EJ, Zeller T, Lohman K, Cornelis MC, Probst-Hensch NM, Kronenberg F, Tonjes A, Hayward C, Aspelund T, Eiriksdottir G, Launer LJ, Harris TB, Rampersaud E, Mitchell BD, Arking DE, Boerwinkle E, Struchalin M, Cavalieri M, Singleton A, Giallauria F, Metter J, de Boer IH, Haritunians T, Lumley T, Siscovick D, Psaty BM, Zillikens MC, Oostra BA, Feitosa M, Province M, de Andrade M, Turner ST, Schillert A, Ziegler A, Wild PS, Schnabel RB, Wilde S, Munzel TF, Leak TS, Illig T, Klopp N, Meisinger C, Wichmann HE, Koenig W, Zgaga L, Zemunik T, Kolcic I, Minelli C, Hu FB, Johansson A, Igl W, Zaboli G, Wild SH, Wright AF, Campbell H, Ellinghaus D, Schreiber S, Aulchenko YS, Felix JF, Rivadeneira F, Uitterlinden AG, Hofman A, Imboden M, Nitsch D, Brandstatter A, Kollerits B, Kedenko L, Magi R, Stumvoll M, Kovacs P, Boban M, Campbell S, Endlich K, Volzke H, Kroemer HK, Nauck M, Volker U, Polasek O, Vitart V, Badola S, Parker AN, Ridker PM, Kardia SL, Blankenberg S, Liu Y, Curhan GC, Franke A, Roach T, Paulweber B, Prokopenko I, Wang W, Gudnason V, Shuldiner AR, Coresh J, Schmidt R, Ferrucci L, Shlipak MG, van Duijn CM, Borecki I, Kramer BK, Rudan I, Gyllenstein U, Wilson JF, Witteman JC, Pramstaller PP, Rettig R, Hastie N, Chasman DI, Kao WH, Heid IM, and Fox CS (2010) New loci associated with kidney function and chronic kidney disease. *Nat Genet* **42**:376-384.
- Kusahara H, Ito S, Kumagai Y, Jiang M, Shiroshita T, Moriyama Y, Inoue K, Yuasa H and Sugiyama Y (2011) Effects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects. *Clin Pharmacol Ther* **89**:837-844.
- Lal R, Sukbuntherng J, Luo W, Vicente V, Blumenthal R, Ho J and Cundy KC (2010) Clinical pharmacokinetic drug interaction studies of gabapentin enacarbil, a novel transported prodrug of gabapentin, with naproxen and cimetidine. *Br J Clin Pharmacol* **69**:498-507.
- Lepist EI, Zhang X, Hao J, Huang J, Kosaka A, Birkus G, Murray BP, Bannister R, Cihlar T, Huang Y and Ray AS (2014) Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat. *Kidney Int* **86**:350-357.

DMD # 67694

- Levey AS, Becker C and Inker LA (2015) Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic review. *Jama* **313**:837-846.
- Levey AS, Perrone RD and Madias NE (1988) Serum creatinine and renal function. *Annu Rev Med* **39**:465-490.
- Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T and Coresh J (2009) A new equation to estimate glomerular filtration rate. *Ann Intern Med* **150**:604-612.
- Maggi P, Montinaro V, Mussini C, Di Biagio A, Bellagamba R, Bonfanti P, Calza L, Cherubini C, Corsi P, Gargiulo M, Montella F and Rusconi S (2014) Novel antiretroviral drugs and renal function monitoring of HIV patients. *AIDS Rev* **16**:144-151.
- Martinez-Guerrero LJ and Wright SH (2013) Substrate-dependent inhibition of human MATE1 by cationic ionic liquids. *J Pharmacol Exp Ther* **346**:495-503.
- Masereeuw R and Russel FG (2010) Therapeutic implications of renal anionic drug transporters. *Pharmacol Ther* **126**:200-216.
- Masuda S, Terada T, Yonezawa A, Tanihara Y, Kishimoto K, Katsura T, Ogawa O and Inui K (2006) Identification and functional characterization of a new human kidney-specific H⁺/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. *J Am Soc Nephrol* **17**:2127-2135.
- Matsui K, Kamijo-Ikemori A, Sugaya T, Ikeda H, Okuse C, Shibagaki Y, Yasuda T and Kimura K (2015) Does elevation of serum creatinine in patients with chronic hepatitis C under therapy of telaprevir mean renal impairment? *Nephrology (Carlton)*.
- Meyer zu Schwabedissen HE, Verstuyft C, Kroemer HK, Becquemont L and Kim RB (2010) Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. *Am J Physiol Renal Physiol* **298**:F997-F1005.
- Miller WG, Myers GL, Ashwood ER, Killeen AA, Wang E, Thienpont LM and Siekmann L (2005) Creatinine measurement: state of the art in accuracy and interlaboratory harmonization. *Arch Pathol Lab Med* **129**:297-304.
- Minejima E, Choi J, Beringer P, Lou M, Tse E and Wong-Beringer A (2011) Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients. *Antimicrob Agents Chemother* **55**:3278-3283.
- Miyazaki H, Anzai N, Ekaratanawong S, Sakata T, Shin HJ, Jutabha P, Hirata T, He X, Nonoguchi H, Tomita K, Kanai Y and Endou H (2005) Modulation of renal apical organic anion transporter 4 function by two PDZ domain-containing proteins. *J Am Soc Nephrol* **16**:3498-3506.
- Morrissey KM, Stocker SL, Wittwer MB, Xu L and Giacomini KM (2013) Renal transporters in drug development. *Annu Rev Pharmacol Toxicol* **53**:503-529.
- Motohashi H, Sakurai Y, Saito H, Masuda S, Urakami Y, Goto M, Fukatsu A, Ogawa O and Inui K (2002) Gene expression levels and immunolocalization of organic ion transporters in the human kidney. *J Am Soc Nephrol* **13**:866-874.
- Motyl W (2004) [The effect of H₂ receptor blockers on renal function. An attempt to accurately measure glomerular filtration]. *Ann Acad Med Stetin* **50**:97-105.
- Muirhead M, Bochner F and Somogyi A (1988) Pharmacokinetic drug interactions between triamterene and ranitidine in humans: alterations in renal and hepatic clearances and gastrointestinal absorption. *J Pharmacol Exp Ther* **244**:734-739.
- Muller F, Pontones CA, Renner B, Mieth M, Hoier E, Auge D, Maas R, Zolk O and Fromm MF (2015) N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction. *Eur J Clin Pharmacol* **71**:85-94.
- Musso CG, Michelangelo H, Vilas M, Reynaldi J, Martinez B, Algranati L and Macias Nunez JF (2009) Creatinine reabsorption by the aged kidney. *Int Urol Nephrol* **41**:727-731.

DMD # 67694

- Naderer O, Nafziger AN and Bertino JS, Jr. (1997) Effects of moderate-dose versus high-dose trimethoprim on serum creatinine and creatinine clearance and adverse reactions. *Antimicrob Agents Chemother* **41**:2466-2470.
- Nakamura T, Yonezawa A, Hashimoto S, Katsura T and Inui K (2010) Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. *Biochem Pharmacol* **80**:1762-1767.
- National Kidney F (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis* **39**:S1-266.
- Nigam SK, Bush KT, Martovetsky G, Ahn SY, Liu HC, Richard E, Bhatnagar V and Wu W (2015) The organic anion transporter (OAT) family: a systems biology perspective. *Physiol Rev* **95**:83-123.
- Nyman U, Bjork J, Back SE, Sterner G and Grubb A (2015) Estimating GFR prior to contrast medium examinations-what the radiologist needs to know! *Eur Radiol*.
- Opravil M, Keusch G and Luthy R (1993) Pyrimethamine inhibits renal secretion of creatinine. *Antimicrob Agents Chemother* **37**:1056-1060.
- Pollak PT, Sharma AD and Carruthers SG (1993) Creatinine elevation in patients receiving amiodarone correlates with serum amiodarone concentration. *Br J Clin Pharmacol* **36**:125-127.
- Prescott LF, Mattison P, Menzies DG and Manson LM (1990) The comparative effects of paracetamol and indomethacin on renal function in healthy female volunteers. *Br J Clin Pharmacol* **29**:403-412.
- Reznichenko A, Sinkeler SJ, Snieder H, van den Born J, de Borst MH, Damman J, van Dijk MC, van Goor H, Hepkema BG, Hillebrands JL, Leuvenink HG, Niesing J, Bakker SJ, Seelen M and Navis G (2013) SLC22A2 is associated with tubular creatinine secretion and bias of estimated GFR in renal transplantation. *Physiol Genomics* **45**:201-209.
- Rizk ML, Houle R, Chan GH, Hafey M, Rhee EG and Chu X (2013) Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation. *Antimicrob Agents Chemother* **58**:1294-1301.
- Rybak M, Abate B, Kang S, Ruffing M, Lerner S and Drusano G (1999) Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. *Antimicrob Agents Chemother* **43**:1549-1555.
- Sakata T, Anzai N, Kimura T, Miura D, Fukutomi T, Takeda M, Sakurai H and Endou H (2010) Functional analysis of human organic cation transporter OCT3 (SLC22A3) polymorphisms. *J Pharmacol Sci* **113**:263-266.
- Sarapa N, Wickremasingha P, Ge N, Weitzman R, Fuellhart M, Yen C and Lloyd-Parks J (2007) Lack of effect of DX-619, a novel des-fluoro(6)-quinolone, on glomerular filtration rate measured by serum clearance of cold iothexol. *Antimicrob Agents Chemother* **51**:1912-1917.
- Schophuizen CM, De Napoli IE, Jansen J, Teixeira S, Wilmer MJ, Hoenderop JG, Van den Heuvel LP, Masereeuw R and Stamatialis D (2015) Development of a living membrane comprising a functional human renal proximal tubule cell monolayer on polyethersulfone polymeric membrane. *Acta Biomater* **14**:22-32.
- Seronie-Vivien S, Galteau MM, Carlier MC, Hadj-Aissa A, Hanser AM, Hym B, Marchal A, Michotey O, Pouteil-Noble C, Sternberg M, Perret-Liaudet A and Creatinine Working Group of the Societe Francaise de Biologie C (2005) Impact of standardized calibration on the inter-assay variation of 14 automated assays for the measurement of creatinine in human serum. *Clin Chem Lab Med* **43**:1227-1233.
- Shemesh O, Golbetz H, Kriss JP and Myers BD (1985) Limitations of creatinine as a filtration marker in glomerulopathic patients. *Kidney Int* **28**:830-838.
- Shen H, Liu T, Morse BL, Zhao Y, Zhang Y, Qiu X, Chen C, Lewin AC, Wang XT, Liu G, Christopher LJ, Marathe P and Lai Y (2015) Characterization of Organic Anion Transporter 2 (SLC22A7): A Highly

DMD # 67694

- Efficient Transporter for Creatinine and Species-Dependent Renal Tubular Expression. *Drug Metab Dispos* **43**:984-993.
- Shen H, Yang Z, Zhao W, Zhang Y and Rodrigues AD (2013) Assessment of vandetanib as an inhibitor of various human renal transporters: inhibition of multidrug and toxin extrusion as a possible mechanism leading to decreased cisplatin and creatinine clearance. *Drug Metab Dispos* **41**:2095-2103.
- Shitara Y, Sato H and Sugiyama Y (2005) Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. *Annu Rev Pharmacol Toxicol* **45**:689-723.
- Somogyi A and Bochner F (1984) Dose and concentration dependent effect of ranitidine on procainamide disposition and renal clearance in man. *Br J Clin Pharmacol* **18**:175-181.
- Somogyi A, Stockley C, Keal J, Rolan P and Bochner F (1987) Reduction of metformin renal tubular secretion by cimetidine in man. *Br J Clin Pharmacol* **23**:545-551.
- Suzuki F, Suzuki Y, Sezaki H, Akuta N, Seko Y, Kawamura Y, Hosaka T, Kobayashi M, Saito S, Arase Y, Ikeda K, Mineta R, Watahiki S, Kobayashi M, Nakayasu Y, Tsuda H, Aoki K, Yamada I and Kumada H (2013) Exploratory study on telaprevir given every 8 h at 500 mg or 750 mg with peginterferon-alpha-2b and ribavirin in hepatitis C patients. *Hepatal Res* **43**:691-701.
- Tamai I (2013) Pharmacological and pathophysiological roles of carnitine/organic cation transporters (OCTNs: SLC22A4, SLC22A5 and Slc22a21). *Biopharm Drug Dispos* **34**:29-44.
- Tanihara Y, Masuda S, Sato T, Katsura T, Ogawa O and Inui K (2007) Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. *Biochem Pharmacol* **74**:359-371.
- Tschuppert Y, Buclin T, Rothuizen LE, Decosterd LA, Galleyrand J, Gaud C and Biollaz J (2007) Effect of dronedarone on renal function in healthy subjects. *Br J Clin Pharmacol* **64**:785-791.
- Urakami Y, Kimura N, Okuda M and Inui K (2004) Creatinine transport by basolateral organic cation transporter hOCT2 in the human kidney. *Pharm Res* **21**:976-981.
- Vaidya V, Ferguson M and Bonventre J (2008) Biomarkers of acute kidney injury. *Annu Rev Pharmacol Toxicol* **48**:463-493.
- Vallon V, Eraly SA, Rao SR, Gerasimova M, Rose M, Nagle M, Anzai N, Smith T, Sharma K, Nigam SK and Rieg T (2012) A role for the organic anion transporter OAT3 in renal creatinine secretion in mice. *Am J Physiol Renal Physiol* **302**:F1293-1299.
- Vanmassenhove J, Vanholder R, Nagler E and Van Biesen W (2013) Urinary and serum biomarkers for the diagnosis of acute kidney injury: an in-depth review of the literature. *Nephrol Dial Transplant* **28**:254-273.
- Verhoeven NM, Salomons GS and Jakobs C (2005) Laboratory diagnosis of defects of creatine biosynthesis and transport. *Clin Chim Acta* **361**:1-9.
- Waikar SS, Betensky RA, Emerson SC and Bonventre JV (2012) Imperfect gold standards for kidney injury biomarker evaluation. *J Am Soc Nephrol* **23**:13-21.
- Waikar SS and Bonventre JV (2009) Creatinine kinetics and the definition of acute kidney injury. *J Am Soc Nephrol* **20**:672-679.
- Wang ZJ, Yin OQ, Tomlinson B and Chow MS (2008) OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. *Pharmacogenet Genomics* **18**:637-645.
- Waring WS and Moonie A (2011) Earlier recognition of nephrotoxicity using novel biomarkers of acute kidney injury. *Clin Toxicol (Phila)* **49**:720-728.
- Wittwer MB, Zur AA, Khuri N, Kido Y, Kosaka A, Zhang X, Morrissey KM, Sali A, Huang Y and Giacomini KM (2013) Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling. *J Med Chem* **56**:781-795.

DMD # 67694

- Wu X, Huang W, Prasad PD, Seth P, Rajan DP, Leibach FH, Chen J, Conway SJ and Ganapathy V (1999) Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter. *J Pharmacol Exp Ther* **290**:1482-1492.
- Wu X, Kekuda R, Huang W, Fei YJ, Leibach FH, Chen J, Conway SJ and Ganapathy V (1998) Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. *J Biol Chem* **273**:32776-32786.
- Yonezawa A and Inui K (2011) Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/toxicodynamics and pharmacogenomics. *Br J Pharmacol* **164**:1817-1825.
- Zhang Y, Warren MS, Zhang X, Diamond S, Williams B, Punwani N, Huang J, Huang Y and Yeleswaram S (2015) Impact on creatinine renal clearance by the interplay of multiple renal transporters: a case study with INCB039110. *Drug Metab Dispos* **43**:485-489.
- Zong J, Borland J, Jerva F, Wynne B, Choukour M and Song I (2014) The effect of dolutegravir on the pharmacokinetics of metformin in healthy subjects. *J Int AIDS Soc* **17**:19584.

DMD # 67694

Legends for Figures

Figure 1: Membrane transporters expressed on human renal proximal tubule cells

The transporters located in the basolateral plasma membrane include organic anion transporter 1 (OAT1; SLC22A6), OAT3 (SLC22A8), OAT2 (SLC22A7), organic cation transporter 2 (OCT2; SLC22A2), OCT3 (SLC22A3), and organic anion transporting polypeptide 4C1 (OATP4C1; SLCO4C1). Transporters located in the apical membrane include P-glycoprotein (P-gp; MDR1, ABCB1), multidrug and toxin extrusion protein 1 (MATE1; SLC47A1), MATE2K (SLC47A2), breast cancer resistance protein (BCRP; ABCG2), multidrug resistance protein 2 (MRP2; ABCC2), MRP4 (ABCC4); OAT4 (SLC22A11), urate transporter 1 (URAT1; SCL22A12), peptide transporter 1 (PEPT1; SLC15A1) and PEPT2 (SLC15A2), organic cation/carnitine transporter 1 (OCTN1; SLC22A4) and OCTN2 (SLC22A5).

Figure 2: Schematic representation of the biosynthesis and disposition of creatine and creatinine.

Figure 3: Schematic representation of renal elimination of creatinine and the transporters known to transport creatinine *in vitro*

Table 1. *In vitro* inhibition (IC₅₀ or K_i) of selected compounds on human OCT2, MATE1, MATE2K, OAT2, and OCT3

Inhibitors	OCT2 IC ₅₀ or K _i (μM)		MATE1 IC ₅₀ or K _i (μM)		MATE2K IC ₅₀ or K _i (μM)		OAT2 IC ₅₀ or K _i (μM)	OCT3 IC ₅₀ or K _i (μM)
	Probe Metformin (10 μM) ^a	Reported in the literature ^b	Probe Metformin (5 μM) ^a	Reported in the literature ^b	Probe Metformin (5 μM) ^a	Reported in the literature ^b	Reported in the literature ^b	Reported in the literature ^b
Cimetidine	2.9 ± 0.7	16.6-1650	0.6 ± 0.05	0.2-16.3	5.6±0.7	2.1-46.6	22-72.8	9.8-111
Pyrimethamine	0.61 ± 0.04	4.8-23.6	0.02 ± 0.002	0.077-0.63	0.045±0.003	0.046-0.52	-	-
Famotidine	21.6 ± 3.4	36.1-1800	0.45 ± 0.03	0.6-0.76	6.6±0.9	9.7-36.2	-	6.7-14
Ranitidine	11.7 ± 1.3	30.5-79	8.2 ± 0.6	8.3-25.4	21±2	25	-	62-290
Trimethoprim	19.8±1.5	13.2-1327	0.51±0.03	3.31-29.1	0.14±0.02	0.61-28.9	NI	12.3
Dronedarone	1.9±0.3	-	0.46±0.02	-	8.9±1.7	-	-	-
DX619	-	0.94-1.29	-	0.82-4.32	-	0.1	-	-
Dolutegravir	0.21±0.04	0.066-1.93	3.6±0.7	4.67	12.5±1.6	>100	>100	>100
Cobicistat	37.9±4.9	8.24-33	0.98±0.19	0.99-1.87	20.5±3.0	33.5	>100	>100
Ritonavir	24.8±3.4	20-25	0.28±0.05	0.08-15.4	40.1±6.5	23.7	>20	300
Ranolazine	47 ± 9	-	16.8±1.5	-	50±8	-	-	-
Rilpivirine	0.38±0.05	5.13	0.25±0.04	-	0.28±0.08	-	-	-
Amiodarone	4.7±1.1	>1000	1.0±0.2	-	>50	-	-	>1000
Raltegravir	>100	>100	>100	>100	>100	>100	-	-
Telaprevir	>100	6.35	62±5	22.98	>100	-	-	-
Vandetanib	0.4±0.05	5.5-73.4	0.06 ± 0.01	0.16-1.23	0.04 ± 0.01	0.3-1.26	-	-

-: Data are not reported or available. ^a: Data generated at Merck & Co for inhibition of OCT2, MATE1 and MATE2K using metformin as the probe substrate in CHO-K1-OCT2, CHO-K1-MATE1, and MDCKII-MATE2K cells using the method described by Rizk et al (Rizk et al., 2013). ^b: Data obtained from the University of Washington DDI database (<https://www.druginteractioninfo.org>).

Table 2. Effect of selected compounds on SCr, CL_{cr}, and GFR in humans and the correlation with *in vitro* inhibition of OCT2, MATE1 and MATE2K

Inhibitors	Dosing regimen	SCr ↑ (%)	CL _{cr} ↓ (%)	GFR ↓	Markers for GFR	C _{max} (uM)	f _u	C _{max} /IC ₅₀ ^a			C _{max,u} /IC ₅₀ ^a			References
								OCT 2	MATE1	MATE 2K	OCT2	MATE1	MATE 2K	
Cimetidine	400 mg (QDS)	13-26	20	NS	⁵¹ Cr-EDTA; inulin	8-12	0.8	4.14	20.00	2.14	3.31	16.00	1.71	(Hilbrands et al., 1991) (Dutt et al., 1981)
Pyrimethamine	50-100mg SD	18-26 -	25-27	NS	inulin	2.3 ^a	0.13	3.77	115.00	51.11	0.49	14.95	6.64	(Kusuhara et al., 2011) (Opravil et al., 1993)
Famotidine	40mg QD, 7days	NS	NS	-	-	0.39	0.8	0.02	0.87	0.06	0.01	0.69	0.05	(Ishigami et al., 1989)
Famotidine	200mg SD; 160mg q4h	SI	SI	-	-	1.25	0.8	0.06	2.78	0.19	0.05	2.22	0.15	(Hibma et al., 2015)
Ranitidine	300mg QD	NS	NS	-	-	3.72	0.85	0.32	0.45	0.18	0.27	0.39	0.15	(Motyl, 2004)
Trimethoprim	20mg/kg/day (10 days); 200mg BID	31	16	NS	⁵¹ Cr-EDTA iothalamate	3.4-6.9	0.56	0.35	13.53	49.29	0.20	7.58	27.60	(Naderer et al., 1997; Arya et al., 2014)
Dronedarone	400mg bid 7days	10-15	18	NS	Sinistrin PAH	0.30	0.02	0.16	0.65	0.03	0.003	0.013	0.001	(Tschuppert et al., 2007)
DX-619	800mg (qd) [4 days]	30-40	26	NS	iohexol	20.5-22	0.29-0.35 ^b	23.40	26.83	220.0	8.19	9.39	77.0	(Sarapa et al., 2007)
Dolutegravir	50mg (qd or bid, 14 days)	9-17	10 -14	NS	iohexol Cystatin C	6.7-13.1	0.01	62.38	3.64	1.05	0.62	0.04	0.01	(Koteff et al., 2012)
Cobicistat	150 mg QD, 7 d, p.o.	10.5, 23	8 – 14, 9 - 20	NS	iohexol	1.55	0.03	0.04	1.58	0.08	0.001	0.05	0.002	(Cohen et al., 2011; German et al., 2012); (Arya et al.,

														2014)
Ritonavir	100mg QD	-	25	NS	lohexol	2.16	0.015	0.09	7.71	0.05	0.001	0.12	0.001	(Deray et al., 1998; German et al., 2012; Lepist et al., 2014)
Ranolazine	1000 mg BID, 5 d, p.o.	12	10	NS	Sinistrin	6.01	0.38	0.13	0.36	0.12	0.05	0.14	0.05	(Arya et al., 2014)
Rilpivirine	25mg (qd, 96 weeks)	10	-	NS	Cystatin C	0.6	0.005	1.58	2.40	2.14	0.01	0.01	0.01	Drug label; (Maggi et al., 2014)
Amiodarone	400mg QD	11	-	-	-	0.8-2.3	0.04	0.49	2.30	0.05	0.02	0.09	0.002	(Pollak et al., 1993)
Raltegravir	400mg BID	NS	NS	-	-	3.38	0.17	<0.03	<0.03	<0.03	<0.01	<0.01	<0.01	Drug label; (Rizk et al., 2013; Maggi et al., 2014)
Telaprevir	750mg q8h	SI	-	NS	Cystatin C, L-FABP, NAG	5.82	0.04-0.24 ^b	<0.06	0.09	<0.06	0.01	0.02	<0.01	(Suzuki et al., 2013; Matsui et al., 2015)
Vandetanib	300mg QD	15	-	-	-	0.33	0.1	0.83	5.50	8.25	0.08	0.55	0.83	(Shen et al., 2013)

-: Data are not reported or available. NS: Not significant (either statistically or clinically). SI: Significantly increased compared to baseline level; ^a: IC₅₀ used are generated at Merck & Co and shown in Table 1, except for DX-619, for which lowest IC₅₀ values obtained from the literature are used (see Table 1). ^b: highest f_u values are used to estimate C_{max,u}/IC₅₀ as the worst case scenario. Data generated at Merck & Co 50mg oral SD

Table 3. Examples of transporter related DDIs involving OCT2, MATE1, and/or MATE2K and correlation with transient elevation of sCr

Perpetrator	Perpetrator dose regimen	Victim	Victim dose regimen	% Change in AUC	% Change in renal CL	Elevation of SCr and/or % decrease of CLcr	References
cimetidine	400 mg QID [8 days]	gabapentin	1200 mg QD [4 days]	23.7	-17.8	Yes; CLcr↓10%	(Lal et al., 2010)
cimetidine	800 mg BID [6 days]	glycopyrronium	100 ug Inhalation SD	19.2	-22.1	-	(Dumitras et al., 2013)
cimetidine	400 mg BID [6.5 days]	metformin	500 mg SD	54.2	-44.6	No; CLcr NS	(Wang et al., 2008)
cimetidine	400 mg BID [5 days]	metformin	250 mg QD [10 days]	46.2	-28.3	No ^a	(Somogyi et al., 1987)
cimetidine	300 mg TID [5 days]	varenicline	2 mg SD	29.7	-25.1	Yes ; CLcr↓5-10%	(Feng et al., 2008)
dolutegravir	50 mg BID [7 days]	metformin	500 mg BID [12 days]	145	-	Yes; SCr ↑	(Zong et al., 2014)
pyrimethamine	50 mg SD	metformin	250 mg SD	35.3	-35	Yes; CLcr↓20%	(Kusuhara et al., 2011)
ranitidine	150 mg BID	procainamide	1 g SD	13.7	-18.5	-	(Somogyi and Bochner, 1984)
ranitidine	150 mg BID [4 days]	triamterene	100 mg/day QD [8 days]	-24	-51	No; NS Clcr	(Muirhead et al., 1988)
trimethoprim	200 mg TID [6 days]	metformin	500 mg TID [10 days]	37	-32	Yes; CLcr↓20%; SCr ↑23%	(Grun et al., 2013)
trimethoprim	200 mg TID[5 days]	metformin	850 mg QD [2 doses]	29.5	-26.4	Yes; CLcr↓16.9 %	(Muller et al., 2015)

DMD # 67694

vandetanib	100 mg QD [3 21-day-cycles]	cisplatin	75 mg/m ² SD [3 21-day-cycles]	32.7	-	-	(Blackhall et al., 2010)
vandetanib	800 mg SD	metformin	1000 mg SD	73.3	-52	Yes; SCr ↑ 8-29%,	(Johansson et al., 2014)

^a: a time-dependent variation of SCr was observed. -: Data are not reported or available. NS: Not significant statistically.

Figure 1




Figure 2




Figure 3

